Neuroimaging in schizophrenia;Neuroimaging bei schizophrenen Erkrankungen

Fortschritte der Neurologie Psychiatrie

Volumn 73, Issue SUPPL. 1, 2005, Pages

  Lanzenberger, R ^a   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BIOLOGICAL MARKER; CATECHOL METHYLTRANSFERASE; DOPAMINE; GLUTAMINE; KETAMINE; METIROSINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN 1A RECEPTOR;

BINDING AFFINITY; BRAIN REGION; CONFERENCE PAPER; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; ENZYME METABOLISM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; MORPHOMETRICS; NEUROIMAGING; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC POTENTIAL; PREFRONTAL CORTEX; PRESYNAPTIC POTENTIAL; RECEPTOR BINDING; SCHIZOPHRENIA; SEROTONIN UPTAKE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE;

BRAIN; BRAIN CHEMISTRY; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 28544440481     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-915581     Document Type: Conference Paper

References (110)

1. Olsson H, Halldin C, Farde L. Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. Neuroimage 2004; 22 (2): 794-803
2. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996; 153 (4): 466-476
3. Kapur S, Lecrubier Y. Dopamine in the Pathophysiology and Treatment of Schizophrenia. London; Taylor & Francis Group, 2003
4. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 2004; 7 Suppl 1: S1-5
5. Heinz A. [The dopamine hypothesis of schizophrenia. New findings for an old theory]. Nervenarzt 2000; 71 (1): 54-57
6. Garris PA, Wightman RM. Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J Neurosci 1994; 14 (1): 442-450
7. Heinz A, Saunders RC, Kolachana BS, Jones DW, Gorey JG, Bachevalier J, Weinberger DR. Striatal dopamine receptors and transporters in monkeys with neonatal temporal limbic damage. Synapse 1999; 32 (2): 71-79
8. Heinz A, Braus DF, Romero B, Gallinat J, Puls I, Juckel G, Weinberger DR. [Genetic and pharmacological effects on prefrontal cortical function in schizophrenia]. Nervenarzt 2004; 75 (9): 845-856
9. Schmitt A, Weber-Fahr W, Jatzko A, Tost H, Henn FA, Braus DF. [Current overview of structural magnetic resonance imaging in schizophrenia]. Fortschr Neurol Psychiatr 2001; 69 (3): 105-115
10. Scherk H, Falkai P. [Changes in brain structure caused by neuroleptic medication]. Nervenarzt 2004; 75 (11): 1112-1117
11. Brassen S, Tost H, Hoehn F, Weber-Fahr W, Klein S, Braus DF. Haloperidol challenge in healthy male humans: a functional magnetic resonance imaging study. Neurosci Lett 2003; 340 (3): 193-196
12. Braus DF, Ende G, Hubrich-Ungureanu P, Henn FA. Cortical response to motor stimulation in neuroleptic-naive first episode schizophrenics. Psychiatry Res 2000; 98 (3): 145-154
13. Bertolino A, Blasi G, Caforio G, Latorre V, De Candia M, Rubino V, Callicott JH, Mattay VS, Bellomo A, Scarabino T, Weinberger DR, Nardini M. Functional lateralization of the sensorimotor cortex in patients with schizophrenia: effects of treatment with olanzapine. Biol Psychiatry 2004; 56 (3): 190-197
14. Lamelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999; 46 (1): 56-72
15. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998; 42 (3): 211-221
16. Wilson AA, Mccormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P, Ginovart N. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4, 4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 2005; 48 (12): 4153-4160
17. Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 2000; 100 (1): 1-11
18. Verhoeff NP. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacology (Berl) 1999; 147 (3): 217-249
19. Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 1999; 46 (5): 681-688
20. Gefvert O, Lindstrom LH, Waters N, Waters S, Carlsson A, Tedroff J. Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics orclozapine. Scand J Psychol 2003; 44 (3): 289-292
21. Copolov D, Crook J. Biological markers and schizophrenia. Aust N Z J Psychiatry 2000; 34 Suppl: S108-112
22. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Heertum RL van, Cooper TB, Carlsson A, Laruelle M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000; 48 (7): 627-640
23. Laruelle M, Abi-Dargham A, Dyck CH van, Gil R, D'souza CD, Erdos J, Mccance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996; 93 (17): 9235-9240
24. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, De Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997; 94 (6): 2569-2574
25. Riccardi P, Ansari MS, Li R, ZaId S, Park B, Dawan S, Anderson S, Doop M, Woodard E, Schoenberg D, Schmid D, Baldwin RM, Kessler RM. D-Amphetamine induced displacement of [18F]Fallypride uptake in striatal and extrastriatal regions in humans. SNM Abstract Book Supplement 2005; 46 (5): 204
26. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Heertum RL van, Gorman JM, Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000; 97 (14): 8104-8109
27. Verhoeff NP, Kapur S, Hussey D, Lee M, Christensen B, Psych C, Papatheodorou G, Zipursky RB. A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 2001; 25 (2): 213-223
28. Verhoeff NP, Hussey D, Lee M, Tauscher J, Papatheodorou G, Wilson AA, Houle S, Kapur S. Dopamine depletion results in increased neostriatal D(2), but not D(1), receptor binding in humans. Mol Psychiatry 2002; 7 (3): 233, 322-328
29. Verhoeff NP, Christensen BK, Hussey D, Lee M, Papatheodorou G, Kopala L, Rui Q, Zipursky RB, Kapur S. Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacol Biochem Behav 2003; 74 (2): 425-432
30. Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 1995; 378 (6553): 180-182
31. Fletcher PC, Frith CD, Grasby PM, Friston KJ, Dolan RJ. Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia. J Neurosci 1996; 16 (21): 7055-7062
32. Laruelle M, Iyer RN, Al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 1997; 25 (1): 1-14
33. Kasper S, Hale A, Azorin JM, Moller HJ. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999; 249 Suppl 2: II1-II14
34. Kasper S, Tauscher J, Kufferle B, Barnas C, Pezawas L, Quiner S. Dopamine-and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1999; 249 Suppl 4: 83-89
35. Thoma P, Daum I. [Neurocognitive changes and negative symptoms in schizophrenia]. Fortschr Neurol Psychiatr 2005; 73 (6): 333-342
36. Kasper S, Brecher M, Fitton L, Jones AM. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Int Clin Psychopharmacol 2004; 19 (5): 281-289
37. Kasper S, Resinger E. Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 2003; 28 Suppl 1: 27-38
38. Kasper S, Lerman MN, Mcquade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6 (4): 325-337
39. Kasper S. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia. Int Clin Psychopharmacol 2002; 17 Suppl 4: S19-26
40. Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Kufferle B, Barnas C, Stastny J, Praschak-Rieder N, Pezawas L, De Zwaan M, Quiner S, Pirker W, Asenbaum S, Podreka I, Brucke T. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder-implications for psychopharmacology. World J Biol Psychiatry 2002; 3 (3): 133-146
41. Tauscher J, Kufferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl) 2002; 162 (1): 42-49
42. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27 (7): 1159-1172
43. Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, Wilson AA, Houle S, Kasper S, Zipursky RB. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 2002; 59 (6): 514-520
44. Amargos-Bosch M, Bortolozzi A, Puig MV, Serrats J, Adell A, Celada P, Toth M, Mengod G, Artigas F. Co-expression and in vivo interaction of serotoninl A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex 2004; 14 (3): 281-299
45. Puig MV, Artigas F, Celada P. Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cereb Cortex 2005; 15 (1): 1-14
46. Varnas K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 2004; 22 (3): 246-260
47. Abi-Dargham A, Simpson N, Kegeles L, Parsey R, Hwang DR, Anjilvel S, Zea-Ponce Y, Lombardo I, Heertum R van, Mann JJ, Foged C, Halldin C, Laruelle M. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse 1999; 32 (2): 93-109
48. Martin-Ruiz R, Puig MV, Celada P, Shapiro DA, Roth BL, Mengod G, Artigas F. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutarnate-dependent mechanism. J Neurosci 2001; 21 (24): 9856-9866
49. Wang Y, Goldman-Rakic PS. D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons. Proc Natl Acad Sci USA 2004
50. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47 (1): 27-38
51. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999; 21 (2 Suppl): 106S-115S
52. Soares JC, Innis RB. Neurochemical brain imaging investigations of schizophrenia. Biol Psychiatry 1999; 46 (5): 600-615
53. Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry 1999; 4 (5): 418-428
54. Ioannides AA, Poghosyan V, Dammers J, Streit M. Real-time neural activity and connectivity in healthy individuals and schizophrenia patients. Neuroimage 2004; 23 (2): 473-482
55. Huang MX, Edgar JC, Thoma RJ, Hanlon FM, Moses SN, Lee RR, Paulson KM, Weisend MP, Irwin JG, Bustillo JR, Adler LE, Miller GA, Canive JM. Predicting EEG responses using MEG sources in superior temporal gyrus reveals source asynchrony in patients with schizophrenia. Clin Neurophysiol 2003; 114 (5): 835-850
56. Winterer G, Coppola R, Egan MF, Goldberg TE, Weinberger DR. Functional and effective frontotemporal connectivity and genetic risk for schizophrenia. Biol Psychiatry 2003; 54 (11): 1181-1192
57. Tononi G, Edelman GM. Schizophrenia and the mechanisms of conscious integration. Brain Res Brain Res Rev 2000; 31 (2-3): 391-400
58. Peled A, Geva AB, Kremen WS, Blankfeld HM, Esfandiarfard R, Nordahl TE. Functional connectivity and working memory in schizophrenia: an EEG study. Int J Neurosci 2001; 106 (1-2): 47-61
59. Hubl D, Koenig T, Strik W, Federspiel A, Kreis R, Boesch C, Maier SE, Schroth G, Lovblad K, Dierks T. Pathways that make voices: white matter changes in auditory hallucinations. Arch Gen Psychiatry 2004; 61 (7): 658-668
60. Lawrie SM, Buechel C, Whalley HC, Frith CD, Friston KJ, Johnstone EC. Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biol Psychiatry 2002; 51 (12): 1008-1011
61. David AS, Woodruff PW, Howard R, Mellers JD, Brammer M, Bullmore E, Wright I, Andrew C, Williams SC. Auditory hallucinations inhibit exogenous activation of auditory association cortex. Neuroreport 1996; 7 (4): 932-936
62. Dierks T, Linden DE, Jandl M, Formisano E, Goebel R, Lanfermann H, Singer W. Activation of Heschl's gyrus during auditory hallucinations. Neuron 1999; 22 (3): 615-621
63. Lennox BR, Park SB, Medley I, Morris PG, Jones PB. The functional anatomy of auditory hallucinations in schizophrenia. Psychiatry Res 2000; 100 (1): 13-20
64. Bentaleb LA, Beauregard M, Liddle P, Stip E. Cerebral activity associated with auditory verbal hallucinations: a functional magnetic resonance imaging case study. J Psychiatry Neurosci 2002; 27 (2): 110-115
65. Ven VG Van De, Formisano E, Roder CH, Prvulovic D, Bittner RA, Dietz MG, Hubl D, Dierks T, Federspiel A, Esposito F, Di Salle F, Jansma B, Goebel R, Linden DE. The spatiotemporal pattern of auditory cortical responses during verbal hallucinations. Neuroimage 2005
66. Schlosser R, Wagner G, Kohler S, Sauer H. [Schizophrenia as a disconnection syndrome. Studies with functional magnetic resonance imaging and structural equation modeling]. Radiologe 2005; 45 (2): 137-140: 142-143
67. Boksman K, Theberge J, Williamson P, Drost DJ, Malla A, Densmore M, Takhar J, Pavlosky W, Menon RS, Neufeld RW. A 4.0-T fMRI study of brain connectivity during word fluency in first-episode schizophrenia. Schizophr Res 2005; 75 (2-3): 247-263
68. Friston KJ, Frith CD. Schizophrenia: a disconnection syndrome? Clin Neurosci 1995; 3 (2): 89-97
69. Kim JJ, Ho Seok J, Park HJ, Soo Lee D, Chul Lee M, Soo Kwon J. Functional disconnection of the semantic networks in schizophrenia. Neuroreport 2005; 16 (4): 355-359
70. Meyer-Lindenberg AS, Olsen RK, Kohn PD, Brown T, Egan MF, Weinberger DR, Berman KF. Regionally specific disturbance of dorsolateral prefrontal- hippocampal functional connectivity in schizophrenia. Arch Gen Psychiatry 2005; 62 (4): 379-386
71. Meyer-Lindenberg A, Poline JB, Kohn PD, Holt JL, Egan MF, Weinberger DR, Berman KF. Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am J Psychiatry 2001; 158 (11): 1809-1817
72. Davis CE, Jeste DV, Eyler LT. Review of longitudinal neuroimaging studies of drug treatments in patients with schizophrenia. Schizophr Res 2005
73. Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia - therapeutic implications. Brain Res Brain Res Rev 2000; 31 (2-3): 342-349
74. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20 (3): 201-225
75. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 2002; 7 (8): 837-844
76. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23 (3): 285-300
77. Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA, Simkowitz P, Hurley A, Cooper T, Volkow ND, Cancro R. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and HC-raclopride in normal human subjects. Neuropsychopharmacology 1998; 18 (1): 18-25
78. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 1998; 29 (2): 142-147
79. Adams BW, Bradberry CW, Moghaddam B. NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys. Synapse 2002; 43 (1): 12-18
80. Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 2001; 56 (5): 495-507
81. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6 (6): 869-872
82. Kapur S, Seeman P. Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor. Biol Psychiatry 2001; 49 (11): 954-957
83. Walter H, Wunderlich AP, Blankenhorn M, Schafer S, Tomczak R, Spitzer M, Gron G. No hypofrontality, but absence of prefrontal lateralization comparing verbal and spatial working memory in schizophrenia. Schizophr Res 2003; 61 (2-3): 175-184
84. Callicott JH, Mattay VS, Verchinski BA, Marenco S, Egan MF, Weinberger DR. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am J Psychiatry 2003; 160 (12): 2209-2215
85. Mattay VS, Berman KF, Ostrem JL, Esposito G, Horn JD van, Bigelow LB, Weinberger DR. Dextroamphetamine enhances "neural network-specific" physiological signals: a positron-emission tomography rCBF study. J Neurosci 1996; 16 (15): 4816-4822
86. Mattay VS, Callicott JH, Bertolino A, Heaton I, Frank JA, Coppola R, Berman KF, Goldberg TE, Weinberger DR. Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage 2000; 12 (3): 268-275
87. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessiture A, Egan MF, Kolachana B, Callicott JH, Weinberger DR. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 2003; 100 (10): 6186-6191
88. Noga JT, Hyde TM, Herman MM, Spurney CF, Bigelow LB, Weinberger DR, Kleinman JE. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse 1997; 27 (3): 168-176
89. Duncan GE, Sheitman BB, Lieberman JA. An integrated view of pathophysiological models of schizophrenia. Brain Res Brain Res Rev 1999; 29 (2-3): 250-264
90. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 1999; 46 (6): 729-739
91. Gourion D, Gourevitch R, Leprovost JB, Olie HLJP, Krebs MO. [Neurodevelopmental hypothesis in schizophrenia]. Encephale 2004; 30 (2): 109-118
92. Weinberger DR. On the plausibility of "the neurodevelopmental hypothesis" of schizophrenia. Neuropsychopharmacology 1996; 14 (3 Suppl): 1S-11S
93. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, Egan MF, Mattay VS, Hariri AR, Weinberger DR. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005; 8 (6): 828-834
94. Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR, Verchinski BA, Meyer-Lindenberg A, Balkissoon R, Kolachana B, Goldberg TE, Weinberger DR. Variation in DISCI affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci U S A 2005; 102 (24): 8627-8632
95. Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, Egan MF, Meyer-Lindenberg A, Weinberger DR. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 2004; 24 (45): 10099-10102
96. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 2003; 23 (6): 2008-2013
97. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, Goldman D, Weinberger DR. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003; 60 (9): 889-896
98. Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, Altamura M, Nappi G, Papa S, Callicott JH, Mattay VS, Bellomo A, Scarabino T, Weinberger DR, Nardini M. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004; 161 (10): 1798-1805
99. Smolka MN, Schumann G, Wrase J, Grusser SM, Flor H, Mann K, Braus DF, Goldman D, Buchel C, Heinz A. Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J Neurosci 2005; 25 (4): 836-842
100. Heinz A, Braus DF, Smolka MN, Wrase J, Puls I, Hermann D, Klein S, Grusser SM, Flor H, Schumann G, Mann K, Buchel C. Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci 2005; 8 (1): 20-21
101. Ho BC, Wassink TH, O'leary DS, Sheffield VC, Andreasen NC. Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol Psychiatry 2005; 10 (3): 229, 287-298
102. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001; 98 (12): 6917-6922
103. Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, Mcinerney-Leo A, Nussbaum R, Weinberger DR, Berman KF. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 2005; 8 (5): 594-596
104. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, Egan MF, Kleinman JE, Weinberger DR. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004; 75 (5): 807-821
105. Matsumoto M, Weickert CS, Beltaifa S, Kolachana B, Chen J, Hyde TM, Herman MM, Weinberger DR, Kleinman JE. Catechol-O-methyltransferase (COMT) mRNA expression in the dorsolateral prefrontal cortex of patients with schizophrenia. Neuropsychopharmacology 2003; 28 (8): 1521-1530
106. Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF, Weinberger DR. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004; 56 (9): 677-682
107. Silver H, Feldman P, Bilker W, Gur RC. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry 2003; 160 (10): 1809-1816
108. Callicott JH, Egan MF, Mattay VS, Bertolino A, Bone AD, Verchinksi B, Weinberger DR. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 2003; 160 (4): 709-719
109. Goldberg TE, Torrey EF, Gold JM, Bigelow LB, Ragland RD, Taylor E, Weinberger DR. Genetic risk of neuropsychological impairment in schizophrenia: a study of monozygotic twins discordant and concordant for the disorder. Schizophr Res 1995; 17 (1): 77-84
110. Noga JT, Bartley J, Jones DW, Torrey EF, Weinberger DR. Cortical gyral anatomy and gross brain dimensions in monozygotic twins discordant for schizophrenia. Schizophr Res 1996; 22 (1): 27-40